You can advance fundamental nuclear research as CERN does.
ScandiNova has delivered a total of eight custom-made solid-state systems to CERN. The latest, a small test modulator, was delivered in 2017. Compared to the old technology, the most important features are better reliability, pulse performance, more excellent overall stability, and the ability to develop a compact system that takes up less space.
You can generate the brightest x-ray source in the world as MaxIV laboratory does.
An emitted electron beam is accelerated by RF pulses produced by 20 ScandiNova RF systems. At the end of the accelerator, the electron beam is deflected to create X-ray light that can be used to investigate different materials in detail. The X-ray light created by MAX IV will display greater brilliance than any other X-ray source currently in use.
You can beat cancer as Varian Medical Systems does.
Since 1948, the California based company has been a leader in helping to advance radiotherapy, radiosurgery, and many other vital cancer-fighting tools. Their impressive portfolio of innovations has shown repeatedly that cancer is beatable. Together with ScandiNova, they have taken another remarkable leap in cancer treatment.
You can develop groundbreaking cancer treatment technology as Elekta does.
ScandiNova is part of Elekta’s most significant investment in cancer treatment to this date – Unity. Elekta Unity combines magnetic resonance imaging (MRI) and radiation therapy, making it possible to see the target and identify soft tissue during treatment and providing excellent precision beam delivery that is tailored to target the tumour and at the same time protect the patient.
You can develop the next generation proton therapy system as AVO does.
Advanced Oncotherapy (AVO) is a specialist developer and provider of the next generation of particle therapy systems that make radiation less toxic for patients. AVO focuses on the development of a proprietary proton therapy system. The objective is to maximise the destructive effect of radiation on tumours whilst minimising damage to healthy tissues.
